
How Recruiting Top Players Sets the Stage for Medtech Success
Interview with Joe Rafferty, CEO of Vesteck
About the Guest
Joe Rafferty is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. He brings a comprehensive understanding of the challenges and opportunities in the field with his deep interventional medtech background. Joe is currently serving as the CEO of Vesteck, an early-stage device company developing solutions for aortic aneurysms.
Interview Summary
The medtech industry thrives on individuals with diverse expertise and a relentless drive for innovation. Among these remarkable professionals stands Joe Rafferty, the CEO of Vesteck, an accomplished leader in the field with a profound understanding of interventional cardiology, oncology, and radiology. As such, he has left an indelible mark on various organizations with his unparalleled ability to design, build, and commercialize a variety of medical devices.
Throughout his dynamic career, Joe has excelled in critical areas such as early-stage development, go-to-market strategies, product launches, and commercialization at scale. His proficiency extends to vital management aspects, including revenue planning, compensation, KPI oversight, and turnaround strategies.
At the helm of Vesteck, Joe leads a seasoned team dedicated to pioneering transformative solutions for aortic aneurysms. Their groundbreaking technology revolves around suturing endovascular aortic repair grafts to the aorta, both during the initial implantation and subsequent repairs. By preventing graft migration and leaks that typically necessitate complicated and expensive fixes, Vesteck's innovative devices offer significant advantages to both physicians and patients.
Key Learnings From Joeโs Experience
Recruit the right people and find ways to keep them on board. Compared to working with contractors, developing in-house capabilities for critical functions like R&D gives you greater control and saves you from unanticipated delays.
Proficiency in interpersonal communication is indispensable. Donโt hesitate to seek guidance, as mentors can be especially helpful during the early stages of your startup. Also, make sure you understand what investors are looking for in order to increase your chances of raising capital.
For a successful commercial launch, single out top performers within your team, conduct a thorough market analysis, and implement effective positioning strategies. Hiring exceptional talent and executing a well-defined plan will set your company up for revenue growth.
Enhancing In-House Capabilities
For a startup, the transition from alpha to beta builds and subsequent iterations are pivotal, especially during the early stages. Drawing from his wealth of experience in product development, Joe underscores the crucial role of assembling a skilled in-house team for efficient prototyping and R&D: "When you've got rockstar engineers, you don't need to wait for a contract manufacturer or contract R&D person to fit you back into the queue and try to develop the ideas that you brought to them."
By harnessing the expertise of exceptional engineers within your company, you can sidestep the pitfalls and delays that often occur with external partners. Joe astutely highlights the potential downsides of placing undue reliance on contract manufacturers, whose engagement wavers like a โsinusoidal wave,โ to use his words. Once you step away, they need to allocate their hours to the next client or the following project, resulting in a discontinuous workflow.
In Joeโs case, working alongside engineers who can iterate quickly and act on physician feedback, Vesteck was able to move through early development efficiently while ensuring clinical input was incorporated in a meaningful way.
Fundraising Strategies for Success
Fundraising is a challenging journey. It requires determination, resilience, and a strategic approach. Having traversed the landscape himself, Joe shares valuable insights on overcoming challenges and securing the initial investments that are the lifeblood of a startup.
At the crux of his wisdom lies the importance of perseverance and unyielding tenacity. According to Joe, these virtues distinguish the triumphant trailblazers from the rest: "If it was easy, anybody could do it. That's why you're here. So get on with it," he says. It takes determination and willingness to put one foot in front of the other, even when faced with obstacles.
Joe ardently advocates for seeking guidance and counsel from seasoned mentors who have scars from pursuing similar paths. He admits he didnโt make it all come true all by himself: "There are some wonderful mentors that have been very kind to me from a business standpoint, teaching me the do's and don'ts in the early stages." And this was pivotal in his success in product development and market penetration.
On another note, most investors want to know that a leader is coachable and open enough to ask questions, showcasing humility and willingness to learn and improve. The same idea echoed in our conversation with Carol Burns, where we talked about how CEOs need to be comfortable not knowing everything.
Moreover, a good comprehension of the language around raising capital cannot be overstated. Using the right phrases and terminology is essential for effective communication with investors. Understanding the expectations and conventions of fundraising discussions enhances the chances of securing the necessary investments.
Pillars of a Winning Commercial Launch
Launching a device requires meticulous planning, astute market analysis, and deft positioning strategies. Drawing from his rich experience, Joe shares his time-tested strategies for steering startups toward successful commercialization.
His first advice is to identify and nurture the cream of the crop within the organization โ those with unparalleled skills and a proven track record. Building a robust team, fostering their growth, and retaining exceptional talent serve as the bedrock for successful commercialization, and it takes an eye for talent. Joe states, "If you don't know what you're looking for and how to find it, you're done, and an organization will be done quicker than you think." Investing time and effort in selecting the right team members is crucial.
Market analysis and positioning strategies loom large in Joe's approach to commercialization. By delving deep into the intricacies of the target market, comprehending the competitive landscape, and attuning to customer needs, startups can carve out a unique niche that sets them apart. This thorough understanding empowers founders to make informed decisions regarding pricing, marketing, and branding, ensuring maximum impact upon launch.
Joe also cautions against the assumption that regulatory clearance alone means your device is ready. What paves the way for sustained growth and long-term success is a comprehensive approach encompassing both regulatory compliance and a well-crafted go-to-market strategy.
Sponsors
FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.
Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.
Donโt Forget
Interested in advertising with us?
Get in Touch โ
Want to learn from more startup CEOs?
Check Out the Archive โ
Forwarded this email?
Join for Free โ
Who's Scott Nelson again?
See His Bio โ
Transcript
0:00:00 [upbeat music] If it was easy, anybody could do it. That's why you're here. So, you know, get on with it. It's hard. It's not for the faint of heart, and it's not for the people that quit easily.
0:00:12 It does separate, uh, those that have that stickability, that persistence and tenacity from those that don't.
0:00:20 Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.
0:00:27 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. [upbeat music] Hey, everyone.
0:00:41 It's Scott. In this MedSider interview, I sat down with Joe Rafferty, CEO of Vezztek, an early-stage device company developing solutions for aortic aneurysms.
0:00:49 Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices.
0:00:54 He brings a comprehensive understanding of the challenges and opportunities in the field with his deep interventional med tech background. Here are a few of the key things that we discussed in this conversation.
0:01:03 First, recruit the right people and find ways to keep them on board.
0:01:06 Compared to working with contractors, developing in-house capabilities for critical functions like R&D gives you greater control and saves you from unanticipated delays.
0:01:15 Second, proficiency in interpersonal communication is indispensable. Don't hesitate to seek guidance, as mentors can be especially helpful during the early stages of your startup.
0:01:24 Also, make sure you understand what investors are looking for in order to increase your chances of raising capital.
0:01:29 Third, for a successful commercial launch, single out top performers within your team, conduct a thorough market analysis, and implement effective positioning strategies.
0:01:37 Hiring exceptional talent and in- executing a well-defined plan will set your company up for revenue growth.
0:01:43 Before we jump into this episode, I wanted to let you know that we just released the latest edition of MedSider Mentors Volume 3, which summarizes the key learnings from the most popular MedSider interviews over the last several months with folks like Jim Pursley, CEO of Hinge Health, Carol Burns, CEO of Caagent Vascular, and other leaders of some of the hottest startups in the space.
0:02:04 Look, it's tough to listen or read every MedSider interview that comes out, even the best ones, but there are so many valuable lessons you can glean from the founders and CEOs that join our program.
0:02:13 So that's why we decided to create MedSider Mentors. It's the easiest way for you to learn from the world's best medical device and health technology entrepreneurs in one central place.
0:02:22 If you're interested in learning more, head over to medsiderradio.com/mentors. Premium members get free access to all past and future volumes.
0:02:31 If you're not a premium member yet, you should definitely consider signing up. In addition to every volume of MedSider Mentors, you'll get full access to the entire library of interviews dating back to 2010.
0:02:41 This includes conversations with experts like Nadeem Yarad, CEO of CVRX, Renee Ryan, CEO of Cala Health, and so many others. Learn more by visiting medsiderradio.com/mentors.
0:02:54 [upbeat music] All right, Joe, welcome to, uh, MedSider Radio. How are you, Scott? It's a pleasure to be here, and thank you.
0:03:04 I'm humbled that you would even, uh, uh, suggest that I could bring some value to your listeners. So, uh, thank you for the invitation, and I'll do my best to be interesting and informative.
0:03:14 [upbeat music] [laughs] Well, I, I think, I think there's no question that you'll bring some value.
0:03:17 I mean, you've got a, a long, storied, uh, professional career with a ton of, of, uh, learnings and wisdom kind of under, under your belt. So, uh, I think it'll be a fun conversation.
0:03:25 We were chatting in the, in the pre-interview before the discussion how long it's been s- since we actually connected live, you know?
0:03:30 It's been, it's been quite some time, but it's, it's, uh, it's fun to regroup and have these, these conversations, and hopefully they'll be, you know, part fun, part, part educational for everyone listening.
0:03:38 But with that said, if you, if you don't mind, give us, like, a, you know, a two-minute, you know, elevator pitch on your professional background kind of leading up to, uh, you know, your, your current role as CEO of Vezztek.
0:03:48 Yeah. I like to say I'm the luckiest man God ever created, the luckiest Irishman God ever created, and, and usually when folks meet my wife, they confirm that, yes, he is.
0:03:58 [laughs] Um, in my professional career, I was very fortunate to kind of listen to the marketplace and, and whether it was J&J, um, you know, the mechanical products division at J&J, uh, CR Bard getting into, um, you know, some of the, the membrane oxygenators and, and open heart surgery, ACS Guideant with, uh, a- angioplasty and coronary stents.
0:04:22 I was very fortunate to be on the cutting edge of global strategics that were getting into major markets, and the fields were fallow, and you could either...
0:04:33 You either knew how to build a business and grow a business, or you didn't.
0:04:37 And so literally every day it was about moving the needle, and if you could move the needle, uh, obviously it was very reinforcing, and if you couldn't move the needle, obviously it was, it was right there in front of you.
0:04:49 And, um, and so it was a great learning relative to how to build a business, but also retrospectively, if something wasn't working, how to fix it.
0:04:58 'Cause if you knew how to build it, you could kind of go back and look at the drawing board and, and understand where it was falling down and maybe, you know, retool it, if you will.
0:05:07 That basis, that grounding of great business practices was a, kind of a, a, a springboard for me to move into the, um, into the, uh, startup world. Mm-hmm.
0:05:19 You know, the old, the old confidence thing, maybe overconfidence thing.
0:05:22 If you think you're any good, you know, yeah, you're, you're making a lot of money for J&J and Guideant and so on, so, you know, get into the startup world and, you know, prove it. [laughs] Yeah. So.
0:05:32 So true that your, your comment just, like, maybe over- overconfidence, I mean, that, that really resonates with me, 'cause it's like you're, you're doing well ear- early in your, maybe the first half of your professional career in large strategics, and you're like, "I'm gonna take a swing here."
0:05:43 And you think, you think maybe, you know, you're, you're definitely gonna, like, hit a double here. De- maybe, maybe even a triple, perhaps a home run. It's like you get into the startup game and it's like, oof.
0:05:52 Yeah, this, this isn't, this isn't for the faint of, faint of heart, you know? So, uh- Yeah... uh, really, really good, really good point.
0:05:57 And, and for those listening that don't get a chance to, um- Or that do get a chance, I should say, to go, to get to the, uh, the, the full interview summary for this particular discussion.
0:06:05 We'll link to Joe's, uh, LinkedIn profile, um, on MedCider, but you can kind of check out, like, all of the various positions and roles that he's had and teams that he's led throughout his career.
0:06:15 It's kind of one of those things, Joe, when I look at your background, it's like when...
0:06:17 I, I remember early- earlier in my, in my career when I was kind of just getting started, it was like I, I looked at someone like you and you're like, "Wow, that guy has been... has done a lot, you know, in his career."
0:06:26 It's like, wow, these are, these are probably some amazing, amazing stories along the way. But let's focus in on a little bit, uh, on Vestec, and then we'll kind of go back in time.
0:06:33 But you've been at it with Vestec since, uh, it looks like around mid-2019, early to mid-2019.
0:06:39 Give us a sense for kind of what, what your tech- what you're doing with your technology now, what it does, and then maybe, maybe a, a sense for the kind of the origin story or how, how this even came, came to be.
0:06:48 A colleague of mine, a good friend, uh, brought this technology to me.
0:06:51 I, I had finished with a project and, and rang up a close friend who was a, an entrepreneur and an engineer, and he introduced me to a couple of physicians, uh, Johnny Doga and Terry Richard.
0:07:03 Doga is a general surgeon from the time when, when general surgeons were the king of the hill. And Richard, Dr. Richard, is a CT surgeon from Paris.
0:07:13 And, um, and they brought to me a technology, and kind of the summary of the technology is physics is a cruel mistress, and if you cross her, be sorry.
0:07:23 When they, as surgeons, looked at the early endovascular grafting space, they said, "Well, of course this won't work," because the physics of an aneurysm are such that you put radial force on already diseased tissue and it's gonna continue to dilate and give way.
0:07:42 So what they did was they created a catheter that has these nitinol sutures already laid flat.
0:07:50 If, uh, for those of us that were in the peripheral vascular, cardiovascular space, when they make those nitinol stents, they take a hypotube and they laser cut the hypotube in the shape that they want it.
0:08:03 So we do that with our sutures. We've got nitinol sutures that are preformed in a circle.
0:08:09 We preload them in a catheter, and we can deliver them securing the endovascular graft to the aorta either at the initial implant or when the patients come back.
0:08:20 And there are about a million patients around the world that have these grafts in place, and, and unfortunately, they're failing at a quite an alarming rate. So when Dr. Doga and Dr.
0:08:31 Richard brought this technology to me, as you know, I've been in the, the space forever. I called one of my best friends, Dr. Ramaya, Venky Ramaya from Arizona Heart. I asked him to be candid.
0:08:42 He- that's the way Venky is and, and I said, "Tell me about the problem, tell me about this concept, and is it a solution?" And he said, "It's a bit of a, of a challenging secret."
0:08:52 I was gonna say dirty little secret, but these endovascular grafts are, are moving, they're leaking, and they're causing quite a problem.
0:08:59 And Venky's comment to me was, "If your device does what they say it will do, you have a wonderful solution, a very, a very simple solution to a, a problem that's global." Hm. Um, and, and so Venky doesn't mince words.
0:09:15 If it was, if it was not good, he would, he would share his thoughts with me. And what he did was he said, um, "You, you need to get involved in this." And- Hm...
0:09:23 in fact, Venky is, is, uh, on our advisory board, scientific advisory board. And maybe as a testimony to, to how important the project is, Dr.
0:09:35 Sean Lyden is the chairman of the Department of Vascular Surgery at Cleveland Clinic. He's our chief medical officer. Dan Claire is down at Vanderbilt now.
0:09:44 Dan is the chairman of the Department of Vascular Surgery at Vanderbilt. Dan was at Cleveland Clinic. Um, Dan's on our advisory board. Andrew Holden down in, in New Zealand. Uh, Ramon Verko.
0:09:56 We've got kind of the who's who involved relative to communicating the real gravitas, the, the, the challenge that is, that patients are experiencing in the market today. Um, you know, they, they get these grafts in.
0:10:12 They have to be monitored. They have to get a CT scan every year to make sure the grafts haven't moved or leaked. Hm.
0:10:18 So it's, it's kind of like, you know, living with a cancer type thing where you thought you were healed, you thought you got fixed, but you really didn't. Hm.
0:10:26 That, that, that graft without endo anchors and endosutures is what we call ours, without endosutures it can move and leak and you're, you know, you're back in the hospital with a really complex repair that'll, that the majority of the time ends up being an open surgical procedure.
0:10:43 Hm. You know, years down the road. Nobody's ever healthier years down the road. Not usually, anyway. So, uh- Yeah... does that answer your question? It, it does. It does.
0:10:50 And for those listening that, that haven't spent time in the, in the kind of the, the cardiovascular peripheral vascular space, so I- if I- on a patient, I have a, you know, an, an a- aortic aneurysm, sort of like a, a, a distention in your aorta.
0:11:02 This one, one example would be I have... I get a, a, a stent graft placed, right?
0:11:05 So it's a graft that kind of almost seals up that aneurysm and, but the problem is, as you mentioned, Joe, is that these often, they, they begin to leak. They can, uh, they can move, et cetera.
0:11:15 And so the- there's not a lot of great solutions to, to solve for that. Mm.
0:11:18 Vestec, you, you allow a, a physician to, uh, through an endovascular approach, is my understanding, deliver a catheter and almost s- secure that graft in place to prevent it from, from moving, leaking, et cetera.
0:11:29 Is that kind of, uh- You, you- You got it?... it, you, you nailed it right on the head. And, and the key is we're, we're literally creating a hybrid procedure. Yeah.
0:11:38 In, in the open surgical repair they're literally attaching the graft to the aorta.
0:11:43 We're bringing the aorta to the graft, and we want to create those adhesions so that the aorta's not going anywhere and the graft's not going anywhere. Got it.
0:11:52 And that patient, as you say, that blood is excluded from flowing into the aneurysm. Got it. Then it's, it's depressurized. Cool.
0:11:59 You're- This is my inter- my pitch, my interview, uh, you know, pitch for, for joining the team. No. Um, jo- joking aside, where...
0:12:05 So gi- give us a sense for kind of where you guys are at in terms of, you know, uh, development, regulatory, commercialization.
0:12:11 When the technology was brought to me the Intellectual property had a number of years left on it, and my awareness through listening to Global Strategics was, you know, they, they'd love a, a clean sheet of paper and 20 years of runway on any product that they would, they would buy.
0:12:28 Additionally, uh, Kent Stalker, uh, who was a, a key person at ECS Guiden with their stents, their, their carotids, their peripherals.
0:12:37 Kent Stalker is our COO and VP of R&D down there in that Temecula, Carlsbad area, and Ted Wolfman and I worked together at, uh, not only at, at ECS Guiden, but up at Pathway Medical. Right.
0:12:50 Ted was the, uh, one of the founders and inventors of Pathway in addition to Rotablator. So Ted's down there. I gave Ted and Kent the technology and said, "Look, we need to arguably reinvent this.
0:13:03 We can wrap IP around it for the next 20 years."
0:13:07 And so what they did was they took a fantastic idea and, and they made it even better, much more elegant and, and frankly, uh, we've got w- we'll have 8 or 10 or 12 different patents on this technology so that a potential M&A partner now has a clean runway for 20 years.
0:13:26 And what they were able to do is really strip down and make...
0:13:31 Physicians have told us the device and the delivery system is elegantly simple so that from a manufacturing standpoint, it's very low cost, and from a, a, a call it repeatability or consistency of performance, it's a very high consistency type of a, of a manufacturing process.
0:13:51 Got it. So we got the best of both worlds. We've got patents. We've got an, a design for manufacture and a design for a low-cost manufacture. And frankly, all of that was done begin with the end in mind.
0:14:03 Here's, here's what we need, team, and let's go, let's go do it. Yeah, yeah. And boy, did they, they really succeeded quite nicely. I think, I think, uh, you mentioned Carlsbad, uh, Temecula in, in Southern California.
0:14:15 You know, a- uh, Guiden was... I, I, I'm, uh...
0:14:18 I think they still have a facility in, in Temecula, but it's like, it's one of those hotspots that's sort of underappreciated, you know, in terms of engineering talent, you know? Mm-hmm.
0:14:24 'Cause obviously a great, great place to live in terms of the, the, the climate, you know? And, um, and, uh, you know, it's just a lot of legacy, you know, uh, experience there.
0:14:32 Yeah, so yeah, kind of one of those underappreciated engineering, uh, med tech engineering hotspots for sure. Yeah, you're a thousand percent correct.
0:14:40 And frankly, we got a lot of pushback about not using a contract R&D or a contract manufacturer, but my comment was exactly what you just said.
0:14:49 When you've got people like Ted Wolfman and Kent Stalker, who have done the startups before- Mm-hmm... but also can go right back into their R&D lab- Mm-hmm...
0:15:00 and implement exactly the, the suggestions that our physician founders and SAB members have suggested, it's really cut our development time and our IP, y- you know, wraparound.
0:15:12 Cut all that, the expenses and, and the timeline, cut it way, way back- Yeah... by having all that inside. Got it. So- And then so, so just real quick, are you guys... You're, you're in human I think, right? I believe.
0:15:23 Correct. Yeah. Are you, are you actively commercializing it or just focused on clinical trials right now? Yeah. We're communicating. We've done four pre-subs, pre-submission meetings with FDA.
0:15:32 Dorothy Abel is, is, uh, one of our, um, FDA consultants and her mantra has been from the beginning, uh, "Communicate early and often with FDA so you don't run into those costly, uh, surprises."
0:15:45 So FDA is, has essentially, uh, given us a, a lot of very positive feedback on every aspect of what we're doing.
0:15:53 We're doing first in-human experiences for investors and also to validate the device before we roll into our 100 patient w- 12-month follow-up IDE. Got it. So we'll do a, a 510[k].
0:16:08 Aptys or Helifix is our predicate device. The FDA's confirmed that. We'll do 100, 105 patients and, um, and do a 12-month follow-up.
0:16:17 We'll probably consent them for five years because we wanna track from a marketing and, uh, standpoint, we wanna know how, uh, long-term the, uh, the device succeeds. But from an FDA standpoint, it's 12 months. Got it.
0:16:32 So, uh, so yeah, right now we've done five in humans. We'll probably do another five more, and part of that messaging is to de-risk for, uh, investors that, you know, this device works and it works consistently.
0:16:46 And physicians, it's, it's not just a, a device that only the elite can use, that it really is a, a device that's very simple and very straightforward that Joe Sixpack in the community hospital can use and, and use very safely.
0:17:01 Got it. So. Got it. Super, super helpful. Um, and those first in human patients are OUS or are they, are they... Yeah. Yeah. We, we've done two in Riga, Latvia. Dr. Denise Crevans is a rock star.
0:17:14 He's been involved in lots of, uh, studies that you know. He was involved in Nelix. Somebody told me he was the, the top enroller in LimFlow- Hmm... um, and projects like that.
0:17:24 And so he's very prominent OUS and, you know, you get to the Veith meeting and everybody knows him. Um, we've also been up in Canada, Dr.
0:17:32 Bao Bui, who was involved in the very early Medtronic graft clearance, uh, studies. You know, he's been around forever, was involved in Aptys. Dr. Bui's done three cases. Um, let's see. Uh, Sean Leiden went up to Canada.
0:17:48 Venky went up to Canada. Dai Yamanouchi went over to, uh, Latvia, uh, with us. Uh, Dai's now the professor of the Department of Vascular Surgery at, uh, excuse me, the chairman of the Vascular Surgery at Fujita- Hmm...
0:18:03 Hospital there in, um, in Japan. So yeah, we've got five done. Uh, next week we're actually headed over, back over to Riga to do three more, and w- we're actually getting ready to head down to Australia.
0:18:16 We've, we've got a wholly owned subsidiary In Australia, Vestech Australia. We'll take advantage of some, uh, tax credits, we'll take advantage of, uh, of a great clinical environment down there, and great operators.
0:18:29 And, um, and we'll do some, some additional cases down there. So. Okay. Cool. Mm-hmm. Awesome. That's, uh, that sounds like a, sounds like a lot of fun.
0:18:37 And, and listening to you kind of describe everyone that's involved, right, in, in, in the company, the clinical work, et cetera, I think that just speaks volumes around, around the importance of just maintaining connections in the, in the space, right?
0:18:48 And, you know, for someone like you that's in the cardiovascular, the peripheral vascular space, it's ob- it's clear that you've done that because you've, you've been able to pull in such an impressive group of, of KOLs, and it just...
0:18:57 It really, it really speaks volumes and, and really shouldn't be, shouldn't be underappreciated how important that is.
0:19:02 But with that said, Jeff, you know, if, if it's cool with you, let's, uh, maybe spend the next 20 minutes or so kind of going back in time and learning a little bit more about, like, the, the very early days of Vestech, and then I'd like to a- answer your questions, just kind of general advice questions about different, you know, kind of functions or areas of, of, of, of a startup.
0:19:17 But- Mm-hmm... let's maybe first talk about prototypes. You mentioned, you kind of told the story around how you had this technology.
0:19:22 It was, you know, uh, whether, whether you want to kind of conit- kind of consider it alpha, you know, your alpha build, but it needed to be reworked. Mm-hmm. And so when you think about,
0:19:31 with all of your experiences in startups, and you think about even just, you know, the, the last several years with Vestech, how do you think med tech entrepreneurs be- should be thinking about those, those early stage, you know, iterations from alpha to beta, et cetera?
0:19:44 You know, especially, you know, under the guise of, you know, you're trying to be really capital efficient at that point, too. So would love to just get your, get your thoughts on how to, how to best do that.
0:19:51 Any, any words of wisdom for other, other founders and CEOs listening to this? Yeah.
0:19:56 We had some really significant conversations with investors about doing this work that you're talking about in-house versus farming it out to contract manufacturers.
0:20:06 And, and what I will endorse wholeheartedly, when you've got the right teammates, Kent Stocker and Ted Wolfman and their team, they brought along two just rockstar engineers, John Whitfield and Kenneth Stocker.
0:20:19 Apples don't fall from orange trees, you know. [laughs] Uh, Kenneth is, is also a rockstar.
0:20:24 So when you've got people like that, you don't need to wait for a contract manufacturer or contract R&D person to fit you back into the queue and try to develop the ideas that you've brought to them.
0:20:38 'Cause part of that whole, uh, working with a contract R&D and contract manufacturer is that it, it is a sinusoidal wave. They're working with you now, but as soon as you walk out the door, they've got...
0:20:50 They have to book those hours with the next, you know, the next vendor, if you will. Mm-hmm. You know, the next, uh, company. And so it's a lot of, as they say in the UK, fits and starts. You know, stops and starts.
0:21:01 And so we were able to mitigate all that because everybody's in-house.
0:21:06 And literally, I can be in Carlsbad in the morning and have a conversation, you know, with, uh, Ted or Kenneth, and by noontime there are two or three prototypes on the table
0:21:17 talking, you know, and we're talking through which is, uh, the best way to go. The other is when you've got that capability and physicians give you that feedback, you know,
0:21:29 o- one of the highest levels of respect you can pay to a, a clinician, a physician advisor, is to do what they ask you to do and get that back to them quickly. Mm-hmm.
0:21:38 And so for our engineers to be able to iterate and take that advice and get it back for an approval or a, or a, an opinion is, is really, really valuable.
0:21:49 And so, um, I've, I've been involved the other way, where you, you're working with contract manufacturers and, um, and I will say this is absolutely a, a faster, more cost-effective, and frankly, the, the output is much higher, uh, way to go with R&D and, and project evolution.
0:22:10 Right. So. Good.
0:22:11 Th- th- those are really good points, and I think, um, you know, if you're listening to this con- th- this discussion and considering or vetting, in the process of vetting, you know, a full CDMO or a contract manufacturer, I think you just, as you mentioned, Joe, it's important just to go into that, that relationship eyes wide open.
0:22:25 Because to your point, it is, it is often ebb and flow. They may be working on... They may have a team that prioritizes your project this week, but then next week it's five others, you know?
0:22:33 And you gotta ask yourself, "How do I keep my project a high priority for them?" You know? Yeah. "How do I, how do I get, get them to focus on it, get their mind share to focus on it?"
0:22:40 It's a, it's a really, it's a really, uh, key, key challenge, and obviously it sounds like you've been able to solve for that in a, in a little bit of a different way.
0:22:46 And I think, you know, just to plug Switchback Medical, which is, uh, one of the, the CDMOs that we work with at, at, at Fastwave, they have a unique model where, um...
0:22:53 And I think they do this with almost every, every project. I, I'm not entirely sure, but I'm pretty sure that's the case, is when, when you work with them, they have a, a team that's solely dedicated to your project.
0:23:02 They're not balancing, you know, three, four, or five others. It's, it's, it's really just an extension of your team, and probably rooted in what exactly you're talking about, right? Is they've seen...
0:23:10 They've, they've gone with the other model and seen just how challenging that can be, and how, how slow and kind of onerous it can be, uh, when, when, you know, you've got a highly talented group of engineers but they're just distracted and, you know, working on too many projects.
0:23:23 So I think it's a, it's a really, really valid point. Yeah. Well, and it makes sense, frankly, when the thing that these contract manufacturers have to sell is an hourly wage. Mm-hmm.
0:23:33 You know, they, they've got engineers, and if they're not, if they're not working on your project and generating revenue for the business, then they've got to be working on something else to generate revenue for the business.
0:23:43 That's, that's the commodity they have to sell is an, is an hourly wage. Right. So anyway, that's what we decided to do early on and, and that's how we got our prototyping done rather quickly. And so it's been...
0:23:55 And frankly, when we did the prototyping and, and the design, that's where all of those patents came from, you know?
0:24:03 So the, the fact that, that our team developed the device and can write all the, uh, the IP around what they developed is, you know, it goes hand in glove. Yeah. So, yeah. Yeah, no doubt. No doubt.
0:24:17 Let's, let's, let's transition to another topic, uh, which is, you know, uh, equally as important if not more, um, which is fundraising, right?
0:24:23 Um, and as the, as you, as you know as the CEO of a, of a startup, other than maybe- Building the team and connecting the right people, you know, keeping money in the bank is maybe the most important or right, right up there, you know, with the [laughs] Mm-hmm...
0:24:34 the key responsibilities as a, as a startup, you know, founder or CEO. So let's discuss this a little bit.
0:24:40 Like, it, it, it's have this belief that, uh, raising capital, especially during the early stages, seed, series A, is probably some of the most difficult challenging capital to raise.
0:24:48 I mean, once maybe you're into series B, series C, not that it gets dramatically easier, but, you know, you de-risk, you're more de-risked at that point, right?
0:24:55 You've got, you know, a, a syndicate ideally of, of investors at that point that are, that are gonna, you know, continue to support, uh, support the company i- if, if you're executing in the, in the right way.
0:25:03 But those early stages are, are, are tough.
0:25:05 So what have you, I guess, what have you learned maybe at either at Vestek or just in previous experiences about, like, what, what it really takes to get, you know, some of those early stage rounds closed?
0:25:15 I, I'm second oldest of nine. Number three of nine was an, an Air Force colonel and a, and a number of different law degrees.
0:25:21 And one of his, his trainings from boot camp back at the Air Force Academy, he always had a lot of very quick and witty remarks. He said, "If it was easy, anybody could do it. That's why you're here.
0:25:33 So, you know, get on with it." And, and I think that's kind of what it comes down to is that, a- as you suggest, Scott, you, you nailed it.
0:25:41 It's hard, and it's not for the faint of heart, and it's not for the people that quit easily. And, um, been joking around about putting one foot in front of the other and being dogged about it. You know, that...
0:25:53 And oh, by the way, reframing it, if you don't enjoy it, then you better get out because- Sure... as you suggest, if it's a drudgery and, um, wears you down, it'll wash you out. It'll blow you out. Mm-hmm.
0:26:04 So you gotta, somehow you gotta learn to reframe it that this is what you're getting paid to do. And, and it does separate, uh, those that have that stickability, that persistence and tenacity from those that don't.
0:26:17 Mm-hmm. And, um, and the other part, I think, very frankly, I've been very fortunate in the Philly area and nationally, there are some wonderful mentors that have been very kind to me.
0:26:27 You know, in, in, in the Philly area, uh, everybody knows the story of Intact. You know, the, this small, uh, short, uh, stent. Well, Bruce Shook essentially did a, a Lazarus job with Intact. Great company.
0:26:41 I, I'm, I'm very close friends with Carol Burns, the, the prior CEO. Uh, great, great people and, and Bruce and, and Carol both, but, uh, Bruce has been a, a wonderful mentor.
0:26:51 Well, you know, he'll, he'll be very gentle as he slaps you around and- [laughs]... suggests that, you know, don't ever say that. That's a pretty s- silly thing to say.
0:27:00 So having folks like that, A- Adam Dakin in Philly at Dream Adventures is a, is kind of an incubator startup here in Philly.
0:27:07 Um, Adam's a, a brilliant guy, and he's been a great, uh, a great advisor and mentor from a, a business standpoint and, and, uh, helping coach the, the do's and don'ts of those, of those early stages.
0:27:21 Their phraseology that I've embraced, 'cause as, as salespeople early on, we, we all know that, that the J&Js of the world, the, the Bards of the world, they give you a phraseology so that y- you speak in the vernacular.
0:27:34 Embracing that phraseology helps a lot, and you get VCs and, and large angel groups shaking their head because you're using the right words.
0:27:42 Things like when they ask you what your valuation is and you say, "Well, the valuation doesn't matter what I think. It's when you slide a term sheet across the desk, and there's a number on it, there's a valuation."
0:27:53 Mm-hmm. Now we can start a conversation. But bottom line is it, it really doesn't matter what I think. It's what the investor thinks. The market will price the deal. Sure. Period. Period. End of conversation. Yeah.
0:28:05 Um, anyway. That's good stuff. You mentioned, you mentioned C- Carol Burns.
0:28:08 I just, uh, I recently recorded an interview with her, which by, I think by the time this is published, that will have, that will have been, been live as well. But it was great, great conversation with Carol and Dr.
0:28:16 Peter Schneider is on our, our advisory board, so. And then Bruce Shook is- he's always been so helpful, you know, as I've recorded various interviews over the past 10 plus years now. He's always been so...
0:28:25 I mean, I've recorded at least two.
0:28:27 I, I think I recorded two interviews with him now, uh, and he's introduced me to, to a ton of folks, and such a good, right, you know, in terms of just adding, you know, wants to continue to add value to k- the med tech ecosystem.
0:28:36 So all great people. Yeah. But, like, a couple interesting points that kind of really, uh, again, kind of resonate with me, you know, when we talk about fundraising. One is that it's hard, right?
0:28:45 So, like, I, I, I'm sure you come across various founders and CEOs that just, they hate it. They hate fundraising. And it's like, look, it's not easy, and it, it's certainly very, very challenging.
0:28:54 But if you hate something, I think maybe my encouragement would be question whether that should be your role. You know what I mean?
0:29:00 'Cause it's, it's, it's hard, it's challenging, but if you just are constantly hate, it's likely not gonna probably end well. You know, to your point, Joe, you're gonna get washed out.
0:29:07 Uh, you know, it's just not sustainable if you just hate it. So it's, it just gets sort of like about im- you know, I think you shared that story with your brother, kind of embracing it, you know? Uh- Yeah.
0:29:16 That's why you're here... and it's, it's, yeah, it's challen- it's challenging. And then the other thing you mentioned is, is around vernacular, right?
0:29:20 I mean, if you're, if you're having these conversations, whether it's with high net worth individuals, family offices, angels, maybe you're a- actually into your, your full kind of formal rounds.
0:29:28 If you don't kind of understand the process and understand sort of how the game works, the optics of that don't look very well, right? 'Cause they're...
0:29:35 You know, any investor, especially in the early stages, they're putting so much trust, yes, in the technology, but more so the team, right?
0:29:40 Like, is this team actually gonna be a good steward of, of my capital that I'm investing?
0:29:44 And so if you're not tracking, if you're not using, to your point, the same kind of language and vernacular and don't understand kind of, you know, maybe not all of the nuances, but at least have, like, the, the, the foundational basics, it's just, uh, you kind of need to learn up, you know, and maybe reach out to a few people, like you mentioned, that can help, help coach you up in that, that, uh- Yeah...
0:30:00 that process. And, and that's a great way to phrase it, 'cause frankly, there was some good learning up from Bruce and- [laughs]... and Adam and, and a few other folks. So you're- Yeah... you're exactly correct.
0:30:10 And to your point, m- most investors also wanna know that a leader, a CEO, is coachable, and be able to raise your hand and go, "Hey, what is your thought about this?" 'Cause frankly, you can always learn more. Right.
0:30:23 And, and these folks, they do it for a living.
0:30:25 And, um, and so that conversation goes both ways, that they realize that you're- Open and, and I'll use the word vulnerable enough, open, open and coachable enough to ask the question. Right. You know?
0:30:37 And, um, and, you know, if you get your head bit off, great. But if you- [laughs]... you get, if you get the coaching that you want and need, then, you know, that's why you asked the question. Yeah.
0:30:46 So, uh- You mentioned Car- We talked a little bit about Carol Burns, but we talked about this very th- same thing, 'cause sh- she referenced it.
0:30:50 She goes, she's like, "As, as a CEO, you've got to be comfortable, you know, just m- with the fact that you're not, you don't know everything." You know? Right.
0:30:56 There's gonna be thing, there's gonna be gaps, and you just, y- you need to understand that there's gaps and you should, you should have enough confidence and humbleness to just ask questions.
0:31:04 And I think that can be hard.
0:31:05 I mean, I, maybe I'll, I'll speak for myself, but that can be hard if you're kind of early in your, maybe advancing in your career and, you know, you're taking a few shots in the startup game and you have cer- a certain level of confidence.
0:31:15 You know, I think all of us are a bit ambitious if we're doing startups. Mm-hmm.
0:31:18 But, you know, if you've been beaten up a few times, you know, and licked your wounds and, you know, had, uh, had some, m- made a lot of mistakes, failures, you just kind of, you know, h- hopefully over time you'll, you'll get a, you know, you'll, you'll get a sense, and, and again, this is, I'm speaking for me personally, but you just get a sense of like, "I d- I don't know everything."
0:31:34 You know? Um, that, that chip on my shoulder, sometimes it can be good, but sometimes it can be bad. [laughs] You know what I mean? I've got to, got to use that, use that in the, in, in the right way, you know?
0:31:41 So, uh, I think that's just- Yeah...
0:31:43 important, important lesson of just, you know, being willing to, like, just understand that you, you're not gonna know everything, and it's completely okay to bring in the right people and ask, ask questions.
0:31:51 Well, and, and you nailed it on the head. There was a book that I got in, uh, involved teaching years ago called Situational Leadership. Mm. And when building a team,
0:32:03 you know, and, and the analogy is if, if your, uh, your 16-year-old son or daughter just got their driver's license, would you give them the keys to the Porsche and just say, "Hey, go have fun with it," versus you just hired Mario, Mario Andretti, and there's this big Formula 1 race coming up that that is your business, and are you gonna tell Mario Andretti how to drive the race, or are you gonna ask him?
0:32:28 And so if we're fortunate enough to surround ourselves with Mario Andrettis and have that collaboration where, um, there is a, a lot of two-way coaching, you know, they've, they have been there and done it, and they have some ideas on how to run this race.
0:32:43 As President Reagan said, "Trust, but verify." Mm.
0:32:46 Um, you know, how do you want to run the race, and let's talk about it, versus, uh, you know, being one of those hands-off, quote, unquote, "hands-off leaders" and, and giving the 16-year-old the keys to the Porsche, and you know it's gonna end up wrapped around the tree.
0:32:59 So, uh, so kn- knowing where you are and who, who your resources are is pretty critical in that regard. Yeah. So, yeah. Good, good, good, good stuff.
0:33:08 Um, I'm, I'm looking at the clock and I want to be sensitive to your, to your schedule, Joe.
0:33:11 So next couple questions, maybe c- um, I'm gonna try to combine them, but they're, they're related to commercialization, which I know is, is, y- you got so much experience, right?
0:33:17 You get, grew, grew up kind of in the, in the med tech game in, in various commercial roles, uh, before taking on, you know, CEO and, and, and other leadership posi- CEO roles and other leadership positions.
0:33:27 But when you think about... And, and maybe frame...
0:33:30 I, I, I'd like to get an understanding of, like, how involved you are with, uh, National Medical Sales, right, and how that's maybe changed your perspective on commercialization and med tech moving forward.
0:33:38 But maybe c- if, if, I don't want to get too loaded with this question, but, you know, with that in mind, right, what, what do you...
0:33:45 And, and as, as you think about Vestx and just other, other launches that you've been involved with, because there's been so many, you know, what, what do you think, I guess, are, are keys to get right with the commercial launch?
0:33:54 And then maybe kind of weave in your thoughts on how maybe commercializations can change in the future considering you have a lot of experience with, with National, uh, Medical Sales too. Yeah.
0:34:03 One of my biggest takeaways, and, and, and I think we talked about it earlier, about physics being a cruel mistress, that the law of large numbers proves itself out time and time again, that 80/20 rule.
0:34:15 Your best performers you need to embrace, 'cause they're gonna be the best performers. 80% of the revenue is generated by 20%, blah, blah, blah.
0:34:23 And so when you find those warriors, those rock stars, those folks that, that enjoy the fight and win, embrace them and keep them close, because they're the folks you're gonna need for the next battle, whether it's a new product or a new company, whatever.
0:34:38 Those are the folks that you know you've been to war with. They know how to build a business, and they don't shy away from, as, as Tom Murphy down in, in Atlanta says, "They don't shy away from the tip of the spear.
0:34:50 They're right there in front." That's one of the big takeaways, is that, that when you have to go and commercialize, are the early people the folks that can, that can manage that?
0:35:02 And, and are they also, are they also equipped by way of interviewing skills, by way of candidate profile? Do they know what they're looking for and how to look for those q- top 20 percenters?
0:35:18 Because, uh, this, this whole reviewing process, if you don't know how to go through it, behavioral interviewing, if you will, you know, experiences, character traits, and, uh, and skills, if you don't know what you're looking for and how to find it, you know, you're done.
0:35:32 And an organization will be done quicker than, than you think. So, um, keep those folks close to you.
0:35:38 The other interesting thing by way of NMS, but then also, uh, these startups, is so many founders think the device is ready for commercialization.
0:35:48 They, they really haven't done their, their market strategy, their market pricing. They haven't done any positioning. Um, frankly, they really haven't done enough cases to confirm that it's ready to go to market.
0:35:59 They may have their FDA clearance, but is it a commercial product versus a, that gap between, all right, we've got our clearance and we've got a product that we want to take to market.
0:36:10 Oftentimes there are, there are so many aspects to that that a founder, um, that's not a commercial person really does need a lot of coaching on.
0:36:20 One product in remembrance that we, we turned into a few hundred million dollar product, but when they launched, they were arguably giving the product away. Mm.
0:36:29 Literally giving the product away, and obviously that's a, a market model for failure for, for all the, all the obvious reasons.
0:36:37 But coaching, you know, coaching them into how to, you know, some of the best practices was it turned into a, a, a few hundred million dollar project for them- Yeah, yeah... you know, on an annual basis. So- Yeah...
0:36:49 so anyway.
0:36:49 So, so, so crucial, especially that, that latter point around just this, this basic kind of foundational understanding that if you, if you get 510k clearance, PMA, what- whatever regulatory, you know, pathway you're, you're down, De Novo, et cetera, just because you have that in hand doesn't mean you're like, [laughs] you're ready for prime time, you know?
0:37:04 And we've talked quite a bit about, um, especially with other leaders, uh, um, that have come on the, on the, on the program that have a lot of commercial like experience, this, this idea that you, you really need to think about it in, in sort of a, with a certain level of sophistication, your early launch and what that looks like.
0:37:19 And, uh, you know, Bryce Klontz talked a lot about this idea of, you know, so- it's so easy for us to wanna go really wide, right?
0:37:25 Look at, look at the metrics, look at the numbers, look how many accounts we're setting up, but you don't get any sort of penetration, right? You don't... There's no stickiness. Mm-hmm.
0:37:32 And so just kind of thinking about, um...
0:37:33 And I, I would encourage anyone that's, uh, interested in this topic more to, to really go back and listen to that, that in- that interview especially, but that's a really good point.
0:37:39 And I, I think, you know, the, the area that you touched on around, like how do you, how do you actually identify these top performers, right? 'Cause that power law is so, is so true.
0:37:47 And you know, one of my friend, my, my really good friends, Brett Johnston, um, he actually interviewed me. We kind of flipped the, flipped the, the chairs, you know, a, a couple months back.
0:37:55 But this is something that like this, this is his, this is like his, his, his wheelhouse.
0:37:59 And one of the, one of the interesting things that we discussed is like how, how much that's missing in not just a str- ge- fou- you know, startups and, and strategics is that this, this idea that, you know, your regional managers, your VPs, they're not really ever taught like how do you act- like what's the best way to actually interview and identify, uh, people in this process?
0:38:16 'Cause every single sales rep that you're investing in, it is, it is a large investment. It is a significant investment.
0:38:22 And if you're not, if you're not identifying the right people, uh, through various skills and, and techniques during that process, it's just a big, big miss.
0:38:30 And it's, it's always kind of surprising how much that's sort of lacking, you know? And it's, uh, it's not a focus, um, usually in most, in most strategics. Yeah.
0:38:38 One of the, the things that Guident did, uh, way back when really well, they understood that that, as you just suggested, that first level management, second level management, and building those teams out, they were the keys to any organization's success.
0:38:53 To your point, getting the right people in their regions, in their areas is critical. They did a, a program, um, called STARS. It was behavioral interviewing. I rose by any other name.
0:39:05 So if you've got a, an ideal candidate profile, behaviors, uh, character traits, and experiences, uh, skills, and, and you create this profile of what, you know, what, what does Tom Murphy do in this respect?
0:39:20 You create a profile, and, and then you interview to it, but it's those STARS, situation, task, action, result. Tell me what you did when this came up. I don't care.
0:39:31 Don't tell me stories about somebody else or what you would do 'cause in the startup world, you know, we've got lots of folks that wanna get into the startup world, but if they're working for a global strategic and they've never taken a fallow field and grown it from no business,
0:39:48 it's a whole different world. If you've got this whole back office that's there to support and underpin you versus you're in a startup and, and you either know how to do it or you don't, tell me about a time when. Hmm.
0:40:02 And, and you can drill down. It'll reinforce a decision, and oh, by the way, HR loves it 'cause it's quantified. You know, you've got your questions and, and you can keep scorecards.
0:40:13 Um, so it's not that whole, uh, "Geez, in the gut, I really like that person." Yeah. Well, well wh- well why? You know, well now you've got a, a quantifiable process. Yeah.
0:40:23 Um, the, the essence of it is behavioral interviewing. Charlie Johnson, a, a, an ex-US Surgical person taught it. You know, Ethicon used it. Guident used it. And, um, and I think it's paid off in, in,
0:40:36 for me personally, in, uh, spades. So- Yeah.
0:40:39 Such a, such a, such a great point 'cause you, you, you nailed it when you talked about like this, that STAR framework of if you, if the answers that you're getting from the candidate are, "Well, this is what I would do"- Right...
0:40:49 and not, "Hey, this is what I did in the past," whether it was a success or a failure, right? Right. Uh, you... I mean, it doesn't really matter. It's, it's like, "I've been through that before." Mm-hmm.
0:40:58 Um, it's just, I mean, it's, it's so crucial. And you know, I, I, um, I'll mention this.
0:41:01 I, I, I referenced my buddy Brett Johnston, and if you're, if you're listening to this conversation, interested in digging into this, he, he's got like a really great framework of how he approaches it.
0:41:09 And so if you're interested, just, uh, hit me up via, via email, um, uh, scott@scottnelsonlive.com if you're, if you're listening to this, and I'll, I'll certainly make the introduction to, to, to Brett.
0:41:18 But s- so, so important. I'm glad, I'm glad you brought that up 'cause it's, it's so crucial and so often underappreciated, you know, when, when hiring, right?
0:41:25 I mean, uh, you know, for these, uh, for the commercial roles, whether you're in a strategic or, uh- Yeah... or a s- or, or a startup. And I know [laughs] you two mentioned, uh, s- it's so different, right?
0:41:34 Y- I- in a startup it's like you, y- you don't... Like i- if you're asking yourself the question, "Well, who, who's gonna do this for me?"
0:41:40 You know, uh, Lloyd Mensinger, who I had on the program recently, he's like, "You gotta turn around and look in the mirror. It's you. There's no, there's no one else that's gonna do this stuff."
0:41:47 [laughs] "And most of the time it's gonna be, it's gonna be you that's doing it, uh, you know, in, in the, in the, in the startup."
0:41:52 So Joe, I wanna, I wanna leave with, uh, you know, five minutes or so for the rapid fire portion of this interview, but, uh, before we get there, last question.
0:41:57 Um, when you think about Vestx, right, over the next let's, let's call it the next 12 months, what really gets you hyped up?
0:42:02 What, what g- gets you most excited about, you know, looking at, looking at the, the rest of this calendar year, maybe into early, early next year? Yeah. We're, we're raising, uh, 16 million in Series B preferred equity.
0:42:14 A- as you, as we discussed before, it's, it's not easy. That's why you're here. Mm-hmm. We're gonna do another, uh, handful of clinical cases, and then, uh, Series B is gonna fund our, uh, 100 patient clinical trial.
0:42:27 And what's most exciting is, and, and you touched on this earlier, when folks like Dan Clare and Sean Leiden, Venky Ramaiya, are really excited about what we're doing- And we talk about enrolling in this clinical trial.
0:42:40 They, they talk about the patient benefits, and they talk about getting their peers involved in this, in the clinical trial.
0:42:49 They're disappointed because their comments are, "Well, you know, we'll have this trial completed in, like, a month." Mm-hmm.
0:42:55 You know, "We'll, we'll be enrolled in a month 'cause we'll bring in the right people, and we'll get up and done in no time."
0:43:02 And so that's really exciting to hear the excitement in their voice for their patients and, and this technology. You know, it all comes back down to funding. Yeah.
0:43:13 [laughs] Um, when the KOLs that, frankly, you know, they don't suffer fools, you won't... You won't see the people on our advisory board on everybody else's advisory board because they're...
0:43:24 The, the, the team, the Sean Lynes of the world are not bought and paid for. They're, uh... As Ginger Howard used to say, they throw their heart and their mind over the bar and commit. You know, they're not for sale.
0:43:36 Mm-hmm.
0:43:37 And, and I think when our advisory board folks are excited, uh, about what we're gonna do because it's the right reason, it's the right solution for their patients, that and, and the clinical trial are, are very exciting to get started.
0:43:51 Yeah. So that's- That's, that's, uh, yeah, fun, fun times. Uh, not, not for... Not easy, but, uh, challenging, but, uh, but fun, especially if you're...
0:43:58 if you've got a device like, uh, like, uh, Ve- Vestek, where actually you're solving, like, a real, like, a real need, um, in, in, in the space. Yeah. That's always, uh...
0:44:04 It's one of the most probably enjoyable aspects of being in, in med tech. It's not like you're selling some trinket, you know, on Amazon. It's... solves a real, a real patient need.
0:44:11 And so, um, if you're listening to this interview, um, definitely check out vestek.com. So it's V-E-S-T-E-K.com, vestek.com. We'll, we'll, uh, we'll link to it in the f- the full interview summary on MedSider.
0:44:23 Um, and we'll also, uh, provide a link to, to Joe's profile. So if you're potentially interested in the company, investing, et cetera, you, uh, you know who to, who to, who to contact.
0:44:30 So with that said, we'll spend the last maybe few minutes, uh, going through these, these rapid-fire questions. If you wanna answer rapid fire, uh, in, in rapid-fire fashion, that's totally fine.
0:44:38 If you wanna expand a little bit, that's, that's, that's cool too.
0:44:40 So first question: Since taking on the CEO role of, of Vestek, right, uh, we're about four years in probably, I think, at, at this point, what's the most important thing that you've learned? Yeah.
0:44:50 Surround yourself with warriors. Mm-hmm. You know, Ted and Kent are as good as it gets, and we've brought, brought in some other folks, but the, the warriors are, are what it's all about. Hmm. Good stuff. Uh, okay.
0:45:02 So let- let's, let's presume you just got... You just wrapped up, uh, a presentation in front of, you know, 200 life science entrepreneurs, maybe some med tech, biotech that... you know, life science in general.
0:45:11 You're on stage, and y- you wanna leave them with one thing that they really need to take home. What would that be? Patients need it. Payers need it. And the physicians have to have it.
0:45:23 We can give physicians a tool that will help patients not come back. We can save the, the global healthcare community about a billion dollars a year in not repairing these procedures.
0:45:36 And, and so the payers, the providers, and the patients, they all need this solution. Yeah. That three-legged stool, right?
0:45:44 That's a, that's a really, really good framework I, I think for any, any startup, right, um, to be thinking about.
0:45:48 You need to nail all three of those, th- those buckets for, uh, for you to have, uh, have a chance of success.
0:45:53 So any med tech or, you know, health tech, you know, founders or CEOs that, uh, that come to mind that have, have been... We mentioned a few. You know, Carol Burns and, you know, Bruce Shook.
0:46:02 Any, any others that come to mind that have been especially, uh, you know, inspiring to you? Yeah.
0:46:07 As I suggested Bruce, but, you know, y- you could say that, uh, ACS Guidant was, um, you know, a spin-out of Eli Lilly, and it was a big spin-out, but it was a startup.
0:46:18 And frankly, Ginger Howard was a rock star from the minute- Hmm... she walked in there. A straight shooter right in front of you. Very down to earth for, for a brilliant... you know, a, a Harvard Business School grad.
0:46:30 Probably was always the smartest person in the room, but you'd never know it. So her, her humility and, and wisdom, I think, created a culture there at, at ACS that is kinda continuing to expand.
0:46:42 You know, there's lots of, lots of roots out there, and they're all Ginger's roots, so. Got it. Good, good, good stuff. Last question, Joe, before we, uh, we, we put a bow on this.
0:46:51 Um, if you had to rewind the clock, you know, let's frame this up mid to late 20s, early...
0:46:55 you know, fairly early in your professional career, but probably making, making, making some strides, you know, is there one thing that you would, you would tell your younger self, um, at that, at that point in time?
0:47:03 Yeah. Just maintain that humility. My, my wife- Yeah... to this day says, you know, "You Guidant guys, you thought you were it in a bag of chips." And, and frankly, we, we had a lot of fun. We had a lot of success.
0:47:15 And, and I always ask folks as I, as I reconnect with them over the years, you know, we were friends 10, 15, 20, 30 years ago, w- was I going through a, a, a humble phase?
0:47:26 Was I going through an okay phase, or, or was I that egotistical, you know- [laughs]... person? You know, I know we all can... We, uh, can all go through those phases of we're, we're really important people.
0:47:36 And, and so ma- maintaining a, a pulse on, you know, that, that humility and, and, uh, and I'll just say genuineness- Mm-hmm... uh, is, is important. So crucial. I mean, I mean s- such... I mean, I, I, I don't know.
0:47:48 It seems like we've talked a little bit about, a, a fair amount about, about this, this topic, right, of, of humility and, and being humbled, you know, by various, you know, seasons in life, et cetera.
0:47:57 But if I was asked the same question, I, I'd probably say something very similar. It's like you're gonna go through periods of time where y- y- you don't... you just don't have control over things, right?
0:48:06 I mean, you could be doing every- everything the right way. Maybe, maybe you're doing stuff the wrong way, right? Maybe, maybe y- you haven't checked your ego, et cetera.
0:48:12 But there's just so many encounters, right, in, in life, in, in, in business that, uh, that, that are hard and challenging, and, and, and e- and embrace those, learn from them, and, um, just realize you're, you're not, you're not in control of everything, you know?
0:48:23 So... [laughs] Yeah. Yeah. My... And I, I chuckle. My, my mom, uh...
0:48:28 You know, there were nine of us, you know, growing up, and my mom a- and dad had a bunch of sayings, and one of them was, "There but for the grace of God." Mm-hmm. You know?
0:48:35 And, and so that, that humility and that appreciation takes us a long way in life. Yeah. Yeah. Talked about this, one of my favorite books, um, and it, and it, and it's not necessarily a professional book.
0:48:45 It's right, it's right here, uh, by, by John, uh, John Ortberg. I'm not sure if you're familiar with that author, but it's, you know, When the Game is Over, It All Goes Back in the Box.
0:48:53 That's the, that's the title of the book. Uh, I've talked about this on a, a couple different episodes recently, but it's...
0:48:58 If you're in business, and especially s- this, the startup world, I mean, it, it is easy to, to get lost in sort of the, the ambition, the passion of it.
0:49:05 And if you don't realize that, look, I mean, when [laughs] at some point, th- this is, the game's over. You know what I mean? And, uh, it all goes back in the, back in the box.
0:49:13 I mean, it's just a great, a great perspective to kind of, you know- Yeah... live, uh, live life that way, so. You're exactly right. I'm hopefully walking the same talk.
0:49:21 I've been married to the same beautiful woman for for- 43 years. We have four kids and, and, uh, and four grandkids, and they're still talk- they're all still talking to me- [laughs]... which is a great thing.
0:49:30 [laughs] And so to your point, it's those steps along the way and the ability to have that, I'll call it 360-degree view of, of what is important.
0:49:40 And, um, and I feel blessed we're at that point where 43 years later and, and, and the kids are still talking to you. That's a major victory. [laughs] So, so true, especially, especially if you have...
0:49:52 I, I think a fair amount of people listening to this have kids, and it's just, uh, so, so true. I mean, that, that's, uh... They bring so much joy to your life, but are definitely, definitely challenges for sure.
0:50:01 Uh, but, uh- Yeah... with that said, Joe, th- I can't thank you enough for having...
0:50:04 Uh, I'll have you hold on the line here, but thanks, thanks a ton for doing this interview and for kind of sharing a lot of really, really great, great learnings.
0:50:10 Um, and for load the lo- those listening, again, if you don't make it to the, the full interview summary on MedCider, uh, check out vesteck.com, V-E-S-T-E-C-K, vesteck.com. That's the website.
0:50:21 Uh, and then again, we'll link to it on the, on the, on the, uh, the full summary as well as Joe's LinkedIn profile. But, uh, thanks again, Joe, for, uh, for doing the, coming on the program.
0:50:28 Really, really fun conversation. My pleasure, and thank you for the honor. I appreciate it. Yeah. All right.
0:50:32 And for everyone listening, again, Joe, I'll have you hold on, but for everyone listening, you, you, you made it this far. Thanks, thanks so much for your, uh, uh, attention.
0:50:39 Definitely if you head over to MedCider, sign up for the newsletter. We won't, we, we won't spam you. You only, you only hear from us when the next, uh, the next interview goes live.
0:50:45 So, uh, thanks for your attention as always. Until the next discussion, uh, or, uh, MedCider, um, uh, conversation, uh, take care.
0:50:54 [upbeat music] Hey, everyone, let's take a quick break to catch you up on Fast Wave Medical, the company I co-founded and lead as CEO.
0:51:00 We're developing multiple intravascular lithotripsy systems, or IVL for short, for a market size of over $10 billion.
0:51:06 So you may remember the exclusive round of capital I told you we were going to carve out for Fast Wave insiders in the cardiovascular space.
0:51:12 Well, due to the overwhelming demand, we blew through our cap in just a few weeks and had to close it down much earlier than expected.
0:51:18 The incredibly high interest in this exclusive fundraise exceeded even our own expectations. But in retrospect, it sort of makes sense. Here's why.
0:51:25 First, Shockwave Medical, which is the only IVL player in town, has a market cap of close to $10 billion.
0:51:31 Second, we've designed Fast Wave systems to be faster, better, and more efficient and to disrupt this monopolized category by giving physicians more IVL options to choose from.
0:51:40 Third, we've already secured two non-provisional patents from the USPTO, one of which was granted in six months, which is almost unheard of in the med tech space.
0:51:48 We may open up another private fundraise in the future, so if you're interested in joining our waiting list to invest in one of the hottest cardiovascular therapies, head over to fastwavemedical.com/invest and enter your email.
0:51:58 Again, that's fastwavemedical.com/invest. [upbeat music]
